In advanced knee osteoarthritis, platelet-rich plasma is best seen as a bridge therapy prior to arthroplasty (joint replacement), not a replacement for it. That is how the trial authors framed it. Their randomized controlled trial had 90 patients aged 40 to 80. All had painful Kellgren-Lawrence grade 3 to 4 knee osteoarthritis. All were already on arthroplasty waiting lists. Two PRP shots gave bigger six-month gains than cortisone or NSAID pills. That held for both symptoms and blood markers. The authors concluded that this supports PRP as a safe bridge therapy prior to arthroplasty [1]. It holds pain and function while the surgery decision is made. It is not a way to dodge the decision.
That difference is the whole article. Everything below is about how to tell whether a bridge is working for you. And it covers what happens when it is not.
Does PRP help late-stage knee osteoarthritis?
The 90 patients were randomly assigned to one of three groups. One got two PRP injections from their own blood, one week apart. One got a single betamethasone (cortisone) injection. One took aceclofenac tablets, an anti-inflammatory pill. Results were collected at the start, at three months, and at six months. Eighty-two patients finished the six-month follow-up [1].
PRP gave significant and lasting drops in pain scores at three and six months. It beat both the starting scores and both other groups. WOMAC scores track pain, stiffness, and function. Total and sub-scores — pain, stiffness, and function — improved clearly only in the PRP group, at both check points [1].
The opioid finding
Opioid use was clearly lower in the PRP group than in the cortisone and NSAID groups at three months. It was lower than in the cortisone group at six months [1]. Side effects in the PRP group were mild and short-lived.
What it did not measure
The trial followed patients for six months. It reports pain, function, opioid use, and blood markers of inflammation and cartilage turnover. It does not tell you what happens at two years. And it does not report joint imaging.
Can PRP rebuild knee cartilage?
The RESTORE randomized clinical trial compared PRP injected into the joint with a saltwater placebo. Patients had painful knee osteoarthritis with changes on X-ray. At 12 months, MRI showed no significant difference between groups in cartilage volume on the inner shin bone [2]. That result is why we describe PRP in terms of symptoms and function. We never describe it as rebuilding the joint surface.
Holding those two trials together is not a contradiction. A treatment can truly change how a joint feels over months without changing how it looks on imaging. A patient deserves to be told which of those two things is on offer.
Does PRP really work for knee pain?
A 2025 systematic review and meta-analysis pooled 21 randomized controlled trials. They covered 2,406 people with knee osteoarthritis. PRP injected into the joint clearly beat placebo on pain scores and WOMAC scores. It did not beat placebo on KOOS scores [3]. Against a cortisone shot, PRP came out ahead on every pain score in that review.
Preparation matters, and it is not the same from one practice to the next. That is one reason results vary between studies. That variation is a reason to ask what is being prepared and how. It is not a reason to dismiss the whole category.
What does a PRP bridge plan look like?
A bridge only makes sense if it is going somewhere. Before any injection, we set out what the bridge is for. It might be walking farther or handling stairs. It might be taking part in rehab. Or it might be time to plan an operation on your own schedule. We also set how we will know, within a set window, whether it worked.
If the response is not enough, that is information, not a failure. It moves the talk forward instead of repeating the same step. Our orthobiologics overview shows where these treatments fit in the rest of the plan. That includes delivery into the bone and just under the cartilage, and bone marrow aspirate concentrate.
When surgery is the right answer
Regen.MD provides surgery when conservative measures have been exhausted, and Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon. Surgery is never the first move. And a bridge therapy is not a reason to put off an operation you already need. Our conditions and surgical alternatives page describes how that order is decided.
Bring your imaging and your labs to a physician
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
Frequently asked questions
Does PRP rebuild the cartilage in a bone-on-bone knee?
No, and we do not present it that way. The RESTORE randomized trial tested patients with painful knee osteoarthritis. Some got PRP in the joint and some got a saltwater placebo. At 12 months, MRI showed no significant difference in cartilage volume on the inner shin bone. The late-stage evidence supports better pain, stiffness, and function over a set window. That is how we frame it in our evaluation and treatment approach.
If I am on a waiting list for knee replacement, is it too late for PRP?
That is exactly the group the late-stage trial studied. It had 90 patients aged 40 to 80. Each had Kellgren-Lawrence grade 3 to 4 knee osteoarthritis. All were already on arthroplasty waiting lists. The authors concluded the results support PRP as a safe bridge therapy prior to arthroplasty, not as a replacement for it. Study summaries like this are in the library.
How long should I expect a bridge to hold?
The late-stage trial followed patients to six months and reported lasting gains at that point. It does not answer what happens later. We set a review window before the injection. That way the answer for you comes from your own tracked pain and function, not from an average. The physician who reviews that with you is Dr. Gurpreet Singh Padda, MD, MBA, MHP.
Could peptides be used instead of an injection for an arthritic knee?
No. Regen.MD discusses peptides as medical and teaching topics. They are not sold. Nothing in the knee osteoarthritis evidence presents them as a substitute for the treatments studied here. To see how they are handled in a physician-led setting, see peptide and longevity medicine.
What is the downside of PRP injections?
In the late-stage trial, side effects in the PRP group were mild and short-lived. The bigger limits are about what PRP does not do. In the RESTORE trial it did not change cartilage volume on MRI at 12 months. Preparation is also not standardized between practices, which is one reason results vary. Ask what is being prepared, and how, before any injection.
Is PRP better than knee replacement?
They do different jobs. In advanced knee osteoarthritis, PRP is a bridge therapy prior to arthroplasty, not a replacement for it. It holds pain and function while the surgery decision is made. Regen.MD provides surgery when conservative measures have been exhausted. A bridge is never a reason to put off an operation you already need.
Sources
- Lacko M, Awad O, Matúška M, Strážik M, Barej J, et al. Intra-articular platelet-rich plasma demonstrates superior clinical and serum biomarker outcomes compared with corticosteroids and NSAIDs in late-stage knee osteoarthritis: a randomised controlled trial. Journal of Orthopaedic Surgery and Research. 2026;21(1):453. https://doi.org/10.1186/s13018-026-07013-w (referenced for: 90 patients aged 40–80 with KL grade 3–4 knee osteoarthritis on arthroplasty waiting lists; two PRP injections one week apart versus betamethasone or aceclofenac; 82 completed six-month follow-up; VAS and WOMAC outcomes; lower opioid consumption; mild and transient adverse events; the authors’ conclusion supporting PRP as a safe bridge therapy prior to arthroplasty).
- Bennell KL, Paterson KL, Metcalf BR, et al. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021;326(20):2021–2030. https://pmc.ncbi.nlm.nih.gov/articles/PMC8611484/ (referenced for: no significant difference in medial tibial cartilage volume on MRI at 12 months between PRP and saline placebo).
- Pelluri R, Sridevi B, Guntupalli C, et al. Effect of platelet-rich plasma versus placebo or corticosteroid for knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Orthopaedics and Trauma. 2025;62:102890. https://pmc.ncbi.nlm.nih.gov/articles/PMC11772150/ (referenced for: 21 randomized controlled trials, 2,406 participants; significant VAS and WOMAC improvement versus placebo; KOOS not significant; pain scores favoring PRP over corticosteroid).